1 Breast carcinoma. An introduction

Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas

Volumn 1, Issue , 2002, Pages 233-248

  Hayat, M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649382015     PISSN: 18745784     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5784(04)80035-7     Document Type: Chapter

References (125)

1. Al-Kassapodes M., Moore J.H., Orringer M.B., and Beer D.G. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer 54 (1993) 213-219
2. Allen L.F., Lenehan P.F., Eiseman I.A., Elliot W.L., and Fry D.W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer (2002), Pfizer Global Res. Develop., Ann Arbor, MI
3. Allred D.C., Harvey J.M., Berardo M., and Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11 (1998) 155-168
4. Amenta D.C., Hadad S., Lee M., Barnard N., Li D., and Myers J. Loss of types XV and XIX collagen precedes basement membrane invasion in ductal carcinoma of the female breast. J. Pathol. 199 (2003) 298-308
5. Anderson J.M., Ariga R., Govil H., Bloom K.J., Francescatti D., Reddy V.B., Gould V.E., and Gattuso P. Assessment of HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl. Immunohistochem. Mol. Morphol. 11 (2003) 120-124
6. Arnould L., Denoux Y., MacGrogan G., Penault-Lloorca F., Fiche M., Treilleux I., Mathieu M.C., Vincent-Salomon A., Vilain M.O., and Couturier J. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER-2 status in breast cancer. Br. J. Cancer 88 (2003) 1587-1591
7. Ayhan A., Taskiran C., Celik C., Aksu T., and Yuce K. Surgical stage III endometrial cancer: Analysis of treatment outcomes, prognostic factors, and failure patterns. Eur. J. Gynaecol. Oncol. 23 (2001) 553-556
8. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., and Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer 106 (2003) 758-765
9. Bell J., Walsh S., Nusrat A., and Cohen C. Zonula occludens-1 and HER-2/neu expression in invasive breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 11 (2003) 125-129
10. Berchuck A., Rodriguez G., Kinney R.B., Soper J.T., Dodge R.K., Clarke-Pearson D.L., and Bast R.C. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol. 164 (1991) 15-21
11. Berner H., Suo Z., Risberg B., Villman K., Karlsson M., and Nesland J. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42 (2003) 546-554
12. Bhargava R., Neem R., Marconi S., Luszcz J., Garb J., Gasparini R., and Otis C.N. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Hum. Pathol. 32 (2001) 1344-1350
13. Bourguignon L.Y., Zhu H., Chu A., Lida N., Zhang L., and Hung M.C. Interaction between the adhesion receptor CD44 and the oncogene product p185 HER-2 promotes human ovarian tumor cell activation. J. Biol. Chem. 272 (1997) 27,913-27,918
14. Callagy G., Cattaneo E., Daigo Y., Happerfield L., Bobrow L., Pharoah P., and Caldas C. Molecular classification of breast carcinomas using tissue microarrays. Diagn. Mol. Pathol. 12 (2003) 27-34
15. Charafe-Jauffret E., Moulin J., Ginestier C., Bechlian D., Conte N., Geneix J., Adelaide J., Noguchi T., Hassoun J., Jacquemier J., and Birnbaum D. Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells. Int. J. Oncol. 27 (2003) 989-996
16. Colpaert C., Vermeulen P., Benoy I., Soubry A., Van Roy F., van Beest P., Goovaerts G., Dirix L., Van Dam P., Fox S., Harris A., and Van Marck E. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Brit. J. Cancer 88 (2003) 718-725
17. Dabrosin C. Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res. Treat. 80 (2003) 193-198
18. Denoux Y., Lebeau C., Michels J., and Chasle J. Double immunohistochemical labeling technique applied to different types of cytokeratins in epithelial proliferations of the breast. Biotech. Histochem. 78 (2003) 23-26
19. DePaola F., Vecci A., Granato A., Liverani M., Monti F., Innoceta A., Gianni L., Saragoni L., Ricci M., Falcini F., Amadori D., and Volpi A. p27/kip I expression in normal epithelium, benign and neoplastic breast lesions. J. Pathol. 196 (2002) 26-31
20. Deryugina E., Ratnikov B., and Strongin A. Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cell. Int. J. Cancer 104 (2003) 533-541
21. Dorvillus M., Garambois V., Pourquier D., Gutowski M., Rouanet P., Mani J.C., Pugniere M., Hynes N.E., and Pelegrin A. Targeting of human breast cancer by a bispecific antibody directed against two tumor-associated antigens: erbB-2 and carcinoembryonic antigen. Tumor Biol. 23 (2002) 331-341
22. Edgerton S.M., Moore D., Merkel D., and Thor A.D. erbB-2 (HER-2) and breast cancer progression. Appl. Immunohistochem. Mol. Morphol. 11 (2003) 214-221
23. Feldman R., Sementchenko V., Gayed M., Fraig M., and Watson D. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63 (2003) 4626-4631
24. Foekens J., Ries C., Look M., Gippner-Steppart C., Klijn J., and Jochum M. Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br. J. Cancer 88 (2003) 1084-1090
25. Fowler J.E., Bigler S.A., and Farabaugh P.B. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate-specific antigen equal or greater than 4.0 ng. Cancer 94 (2001) 1661-1667
26. Gao Z.O., Gao Z.P., Fields J.Z., and Boman B.M. Development of cross-resistance to tamoxifen in faloxifenetreated breast carcinoma cells. Antican. Res. 22 (2002) 1379-1384
27. Gassel A.M., Backe J., Kreb S., Caffier H., and Muller-Hermelink H.K. Endometrial carcinoma: Immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J. Clin. Pathol. 57 (1998) 25-29
28. Geddert H., Zeriouh M., Wolter M., Heise J.W., Gabbeert H.E., and Sarbia M. Gene amplification and protein overexpression of c-erbB-2 in Barrett carcinoma and its precursor lesions. Am. J. Clin. Pathol. 118 (2002) 60-66
29. Giatromanolaki A., Gorgoulis V., Chetty R., Koukourakis M.I., Whitehouse R., Kittas C., Veslemes M., Gatter K.C., and Lordanoglou I. C-erbB-2 oncoprotein expression in operable nonsmall cell lung cancer. Anticancer Res. 16 (1996) 987-994
30. Grushko T.A., Blackwood M.A., Schumm P.L., Hagos F.G., Adeyanju M.O., Feldman M.D., Sanders M.O., Weber B.L., and Olopade O.I. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 62 (2002) 1481-1488
31. Gullick W., Love S., Wright C., Barnes D.M., Gusterson B., Harris A.L., and Altman D.G. C-erbB-2 protein in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer 63 (1991) 434-438
32. Gupta D., Middleton L., Whitaker M., and Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Anat. Path. 119 (2003) 381-387
33. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocar-cinoma. Hum. Pathol. 25 (1994) 982-993
34. Hammod M.E.H., Barker P., Taube S., and Gutman S. Standard reference material for HER-2 testing. Report of a National Institute of Standards and Technology-sponsored consensus workshop. Appl. Immunohistochem. Mol. Morphol. 11 (2003) 103-106
35. Hayat M.A. Microscopy, Immunohistochemistry and Antigen Retrieval Methods (2002), Kluwer Academic/Plenum Publishers, New York
36. Henne-Bruns D., Vogel I., Luttgcs J., Kloppel G., and Kremer B. Ductal adenocarcinoma of the pancreas head: Survival after regional versus extended lymphandectomy. Hepato-Gastroenterol. 102 (1998) S13-S24
37. Hogsdon J., Chin K., Collins C., and Gray J. Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res. Treatment 78 (2003) 337-345
38. Hoey R., Sanderson C., Iddon J., Brady G., Bundled N., and Anderson N. The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Brit. J. Cancer 88 (2003) 567-573
39. Jarvinen T., and Liu E. HER-2/neu and topoisomerasc II in breast cancer. Breast Cancer Res. Treat. 78 (2003) 299-311
40. Jakubowska A., Narod S.A., Goldgar D.E., Mierzejewski M., Masojc B., Nej K., Huzarska J., Byrski I., Gorski B., and Lubinski J. Breast cancer risk reduction associated with the RAD51 polymorphism among earners of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol. Biomark Prev. 12 (2003) 457-459
41. 1. Cancer Res. 63 (2003) 1696-1705
42. Kato T., Kameoka S., Kimura T., Nishikawa T., and Kobayashi M. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br. J. Cancer 88 (2003) 1900-1908
43. Kauraniemi P., Kuukasjarvi T., Sauter G., and Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am. J. Pathol. 163 (2003) 1979-1984
44. Knuefermann C., Lu Y., Lu B., Jin W., Liang K., Wu L., Schmidt M., Mills G.B., Mendelsohn D., and Fan Z. HER2/Pl-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinomas cells. Oncogene 22 (2003) 3205-3212
45. Kohlberger P., Loesch A., Koelbl H., Breitenecker G., Kainz C., and Gitsch G. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett. 98 (1996) 151-155
46. Kominsky S., Argani P., Korz D., Evron E., Raman V., Garrett E., Rein A., Sauter G., Kallioniemi O., and Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the brea. Oncogene 22 (2003) 2021-2033
47. Kristiansen G., Yu Y., Petersen S., Kaufmann O., Schluns K., Dietel M., and Petersen I. Overexpression of c-erbB-2 protein correlates with disease-stage and chromosomal gain at the c-erbB-2 locus in nonsmall cell lung cancer. Eur. J. Cancer 37 (2001) 1089-1095
48. Kuhn E.J., Kurnot R.A., Sesterhenn I.A., Chang E.H., and Moul J.W. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J.Urol. 150 (1993) 1427-1433
49. Lauffart B., Gangisetty O., and Still I. Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2. Genomics 81 (2003) 192-201
50. Lehmann U., Länger E., Feist H., Glockner S., Hasemeier B., and Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 160 (2002) 605-612
51. Lei S., Appert H.E., Nokata B., Domenico D.R., Kim K., and Howard J.M. Overexpression of HER-2/neu oncogene in pancreatic cancer correlates with shortened survival. Int. J. Panerental. 17.1 (1995) 15-21
52. Lilleby W., Dale F., Olsen D.R., Gude U., and Fossa S.D. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose. Acta. Oncol. 42 (2003) 14-20
53. Marshall C.J. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal regulated kinase activation. Cell 80 (1995) 179-185
54. discussion 92-100. Mass R. The role o HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 27 (2000) 46-52
55. Milde-Langoseh K., Kappes H., Riethdorf S., Loning T., and Bamberger A.-M. FosB is highly expressed in normal mammory epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res. Treat. 77 (2003) 265-275
56. Nakagoe T., Fukushima K., Itoyanagi N., Ikuta Y., Oka T., Nagayasu T., Ayabe H., Hara S., Ishikawa H., and Minami H. Expression ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J. Cancer Res. Clin. Oncol. 128 (2002) 257-264
57. Nakopoulou L., Giannopoulou I., Trafalis D., Gakiopoulou H., Keramopoulos A., and Davaris P. Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters. App. Immunohistochem. Mol. Morph. 10 (2002) 20-28
58. Nakopoulou L., Panayotopoulou E., Giannopoulou I., Alexandrou P., Katsarou S., Athanassiadou P., and Keramopoulos A. Stromelysin-3 protein expression in invasive breast cancer: Relation to proliferation, cell survival and patients' outcome. Mod. Pathol. 15 (2002) 214-219
59. Offersen B.V., Nielsen B.S., Høyer-Hansen G., Rank F., Hamilton-Dutoit S., Overgaard J., and Andreasen PA. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am. J. Pathol. 163 5 (2003) 1887-1899
60. O'Grady A., Flahavan C., Kay E., Barrett H., and Leader M. HER-2 analysis in tissue microarrays of archival human breast cancer. App. Immunohistochem. Mol. Morph. 11 (2003) 177-182
61. Ormandy C., Musgrove E., Hui R., Daly R., and Sutherland R. Cylin Dl, EMS1 and 11ql3 amplification in breast cancer. Breast Cancer Res. Treat. 75 (2003) 323-335
62. Osorio A., De La Hoya M., Rodriguez-López R., Martínez-Ramírez A., Cazorla A., Granizo J.J., Esteller M., Rivas C., Caldéz T., and Benítez J. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int. J. Cancer 99 (2002) 305-309
63. Palmu S., Söderström K.O., Quazi K., Isola J., and Salminem E. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res. 22 (2002) 411-414
64. Paredes J., Milanezi F., Reis-Filho J.S., Leitao D., Athanazio D., and Schmitt F. Aberrant P-Cadherin expression: Is it associated with estrogen-independent growth in breast cancer?. Pathol. Res. Pract. 198 (2002) 795-801
65. Paris P.L., Albertson K.G., Alers J.C., Andaya A., Carroll P., Fridlyand J., Jain A.N., Kamkar S., Kowbel K., Krijtenburg P.J., Pinkel D., Schroder F.H., Vissers K.J., Watson M.J.E., Wildhagen M.F., Collins C., and Dekken H.V. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am. J. Pathol. 162 (2003) 763-770
66. Pegram M., and Reese D. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER-2/neu protein and vascular endothelial growth factor. Semin. in Oncol. 29 (2002) 29-37
67. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dabia P.L., Komminoth P., Lees J.A., Mulligan L.M., Mutter G.L., and Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 155 (1999) 1253-1260
68. Persons D.L., Borelli K.A., and Hsu P.H. Quantitation of HER-2/neu and C-Myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Pathology 10 (1997) 720-727
69. Pfeiffer P., Clausen P.P., Andersen K., and Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein pl85HER-2 in patients with systematically untreated small cell lung ca. Br. J. Cancer 74 (1996) 86-91
70. Plaumann M., Seitz S., Frege R., Estevez-Schwarz L., and Scherneck S. Analysis of DLC-1 expression in human breast cancer. J. Cancer Res. Clin. Oncol. 129 (2003) 349-354
71. Porowska H., Paszkiewicz-Gadek A., Wolczyński S., and Gindzienski A. MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation. Neoplasma 49 (2002) 104-109
72. Press M.F., Slamon K.J., Flom K.J., Park J., Zhou J.Y., and Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast can. J. Clin. Oncol. 20 (2002) 3095-3105
73. Price-Schiavi S., Jepson S., Li P., Arango M., Rudland P., Yee L., and Carraway K. Rat MUC4 (sialomucin complex) reduces binding of anti-ERBB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99 (2002) 783-791
74. Puddefoot J.R., Barker S., Glover H.R., Malouitre S.D., and Vinsow G.P. Non-competitive steroid inhibition of oestrogen receptor functions. Int. J. Cancer 101 (2002) 17-22
75. Reid B.J., Haggitt R.C., Rubin C.E., Roth G., Surawicz C.M., Van Belle G., Lewin K., Weinstein W.M., Antonioli D.A., and Goldman H. Observation variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 19 (1988) 166-178
76. Rhodes A., Jasani B., Anderson E., Dodson A.R., and Balaton A.J. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors. Am. J. Clin. Pathol. 118 (2002) 408-417
77. Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., and Balaton A.J. A formalin-fixed and paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am. J. Clin. Pathol. 117 (2002) 81-89
78. Rolitsky C.D., Theil K.S., McGaughy V.R., Copeland L.J., and Neimann T.H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 18 (1999) 138-143
79. Sadashivan R., Morgan R., Jennings S., Austenfeld M., Van Veldhuizen P., Stephens R., and Noble M. Overexpression of HER-2/neu may be an indicator of poor diagnosis in prostate cancer. J. Urol. 150 (1993) 126-131
80. Sahin A.A. Biologic and clinical significance of HER-2/neu (c-erbB-2) in breast cancer. Adv. Anat. Pathol. 7 (2000) 158-166
81. Santini D., Ceccarelli C., Tardio M., Taffurelli M., and Marrano D. Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast. App. Immunohistochem. Mol. Morph. 10 (2002) 29-33
82. Sauer T., Wiedswang G., Boudjema G., Christensen H., and Karesen R. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: Should in situ hybridization be the method of choice?. APMIS 111 (2003) 444-450
83. Saunders P.T.K., Millar M.R., Williams K., Macpherson S., Bayne C., O'Sullivan C., Anderson T.J., Groome N.P., and Miller W.R. Expression of oestrogen receptor beta (ERβI) protein in human breast cancer biopsies. Br. J. Cancer 86 (2002) 250-256
84. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Green M.I., and Weinberg R.A. The neuoncogene: An erbB-related gene encoding a 185,000-Mr tumor antigen. Nature 312 (1984) 513-516
85. Schroeder J.A., Adriance M.C., Thompson M.C., Camenisch T.D., and Gendler S.J. MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22 (2003) 1324-1332
86. Schwalbe M., Sänger J., Eggers R., Naumann A., Schmidt A., Hoffken K., and Clement J. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int. J. Oncol. 23 (2003) 89-95
87. Seki A., Nakamura K., Kodama J., Miyagi Y., Yoshinouchi M., and Kudo T. A close correlation between c-erbB-2 gene amplification and local progression in endometrial adenocarcinoma. Eur. J. Gynaecol. Oncol. 19 (1998) 90-92
88. Selim A.-G., El-Ayat G., and Wells C.A. Androgen receptor expression in ductal carcinoma in situ of the breast: Relation to oestrogen and progesterone receptors. J. Clin. Pathol. 55 1 (2002) 14-16
89. Shak S. Overview of the trastuzumab (Herceptin) anti-HER-2 monoclonal antibody clinical program in HER-2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26 (1999) 71-77
90. Shin D.M. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 20 (2001) 82a
91. Shirakawa K., Shibuya M., Heike Y., Takashima S., Watanabe I., Konishi F., Kasumi F., Goldman C., Thomas K., Bett A., Terada M., and Wakasugi H. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int. J. Cancer 99 (2002) 344-351
92. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
93. Song Y., Billiar T., and Lee Y. Role of Galectin-3 in breast cancer metastasis. Am. J. Pathol. 160 (2002) 1069-1075
94. Span P., Bussink J., Manders P., Beex L., and Sweep C.G.J. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: Association with treatment outcome. Br. J. Cancer 89 (2003) 271-276
95. Span P., Sweep C.G.J., Manders P., Beek L., Leppert D., and Lindberg R. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with kazal motifs. Cancer 97 11 (2003) 2710-2715
96. Spizzo G., Gastl G., Wolf D., Gunsilius E., Steurer M., Fong D., Amberger A., Margreitr R., and Obrist P. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br. J. Cancer 88 (2003) 574-578
97. Stathopoulou A., Mavroudis D., Perraki M., Apostolaki S., Vlachonikolis I., Lianidou E., and Georgoulias V. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: Comparison of CK-19, CEA, and maspin as detection markers. Anticancer Res. 23 (2003) 1883-1890
98. Suchanek K.M., May F.J., Robinson J.A., Lee W.J., Holman N.A., Monteith G.R., and Roberts-Thomson S.J. Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinogen 34 (2002) 165-171
99. Suo Z., Bjaamer A., Med S., Ottestad L., and Nesland J.M. Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. Ultrastruct. Pathol. 25 (2001) 349-356
100. Tanner M., Jarvinem T.A.H., and Kawanicmi P. Topoisomerase 11α amplification and deletion predict response to chemotherapy in breast cancer. Proc. Am. Assoc. Cancer Res. 41 (2000) 803-abstract
101. Terskikh A.V., Le Doussal J.M., Crameri R., Fisch I., Mach J.P., and Kajava A.V. 'Peptabody': A new type of high avidity binding protein. Proc. Natl. Acad. Sci. USA. 94 (1997) 1663-1668
102. Thybusch-Bernhardt A., Aigner A., Beckman S., Czubayko F., and Juhl H. Ribozyme targetting of HER-2 inhibits pancreatic cancer cell growth in vivo. Eur. J. Cancer 37 (2001) 1688-1694
103. Tolgay O.I., Dolled-Filhart M., D'Aquila T.G., Camp R.L., and Rimm D.L. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not cor. Cancer 97 9 (2003) 1841-1848
104. Townsend P., Dublin E., Hart I., Kao R.-H., Hanby A., Cutress R., Poulsom R., Ryder K., Barnes D., and Packham G. BAG-1 expression in human breast cancer: Interrelationship between BAG-I RNA, protein, HSC70 expression and clinico-pathological data. J. Pathol. 197 (2002) 51-59
105. Tsunoda L., Inada H., Kalembeyi I., Imanaka-Yoshida K., Sakakibara M., Okada R., Katsuta K., Sakakura T., Majima Y., and Yoshida T. Involvement of large tenascin-C splice variant in breast cancer progression. Am. J. Pathol. 162 (2003) 1857-1867
106. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., and Oda S. DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498. Oncology 63 (2002) 48-55
107. Tubbs R.T., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., and Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J. Clin Oncol. 19 (2001) 2714-2721
108. Tubbs R., Pettay J.D., Skacel M., Powell R., Stoler M., Roche P., and Hainfeld J. Gold-facilitated in situ hybridization. Am. J. Pathol. 160 (2002) 1589-1595
109. Umekita Y., and Yoshida H. Expression of maspin gene is up-regulated during the progression of mammary ductal carcinoma. Histopathology 42 (2003) 541-545
110. Van Poznak C., Tan L., Panageas K., Arroyo C., Hudis C., Norton L., and Seidman A. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J. Clin. Oncol. 20 9 (2002) 2319-2326
111. Virmani A., Rathi A., Sugio K., Sathyanarayana U., Toyooka S., Kischel F., Tonk V., Padar A., Takahashi T., Roth J., Euhus D., Minna J., and Gazdar A. Aberrant methylation of TMSI in small cell, non small cell lung cancer and breast cancer. Int. J. Cancer 106 (2003) 198-204
112. Walch A., Bink K., Gais P., Stangl S., Hutzler P., Aubele M., Mueller J., Hofler H., and Werner M. Evaluation of c-erbB-2 overexpression and HER-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal. Cell Pathol. 20 (2000) 25-32
113. Walch A., Specht K., Bink K., Zitzelsberger H., Braselmann H., Bauer M., Aubele M., Stein H., Siewert J.R., Hofler H., and Werner M. HER-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab. Invest. 81 (2001) 791-801
114. Walker R.A. The erb-B/HER type 1 tyrosine kinase receptor family. J. Pathol. 185 (1998) 234-235
115. Wang L., Duke L., Zhang P., Arlinghaus R., Symmans W., Suhin A., Mondez R., and Dai J. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 63 (2003) 4724-4730
116. Wang S., Saboorian M., Frenkel E., Haley B., Siddiqui M., Gokaslan S., Hynan L., and Ashfaq R. Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 15 (2002) 137-145
117. Warshaw A.L., and Castillo F.D. Pancreatic carcinoma. N. Engl. J. Med. 26 (1992) 455-465
118. Wernicke M., Piñeiro L., Caramutti D., Dorn V., Raffo M., Guixa H., Telenta M., and Morandi A. Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: A central role for hyaluronan. Mod. Pathol. 16 (2003) 214-219
119. Wickerham L. Tamoxifen-an update on current data and where it can now be used. Breast Cancer Res. Treat. 75 (2002) S7-S12
120. Wiedswang G., Borgen E., Karesen R., Kvalheim G., Nesland J.M., Qvist H., Schlichting T., Sauer T., Janbu J., Harbitz T., and Naume B. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol. 21 18 (2003) 3469-3478
121. Wittmann B.M., Wang N., and Montano M.M. Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors. Cancer Res. 63 (2003) 5153-5158
122. Wobus M., Rangwala R., Sheyn I., Hennigan R., Coila B., Lower E.E., Yassin R.S., and Sherman L.S. CD44 associates with EGFR and erbB-2 in metastasizing mammary carcinoma cells. Appl. Immunohistochem. Mol Morph. 10 (2002) 34-39
123. Wu A., Seow A., Arakawa K., Van Der Beek D., Lee H., and Yu M. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int. J. Cancer 104 (2003) 450-451
124. Xue S., Lampert I., Haldane J., Bridger J., and Griffin B. Epstein-Barr virus gene expression in human breast cancer: Protagonist or passenger?. Br. J. Cancer 89 (2003) 113-119
125. Yang M., Moriya T., Oguma M., De La Cruz C., Endoh M., Ishida T., Hirakawa H., Orita Y., Ohuchi N., and Sasano H. Microinvasive ductal carcinoma (Tlmic) of the breast. The clinicopathological profil and immunohistochemical features of 28 cases. Pathol. Intern. 53 (2003) 422-428